Lv63
1990 积分 2024-05-13 加入
PSMA PET/CT for Improved Staging Accuracy and Imaging of Neovascularization-associated Features in Primary Lung Cancer
8天前
已完结
[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
1个月前
已完结
Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)
1个月前
已完结
PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer
1个月前
已完结
Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2024;85:217–226
1个月前
已完结
A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
1个月前
已完结
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer
1个月前
已完结
Dosimetry Analysis of 177 Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial
1个月前
已关闭
177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
1个月前
已完结
LUNAR : a randomized Phase 2 study of 177 Lutetium‐PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol)
1个月前
已完结
皖公网安备34019202002308
